VRUS Related New Coverage
-
Shares of Achillion Pharmaceuticals (ACHN) Continue Higher Into The Close
-
Piper Jaffray Starts Pharmasset (VRUS) at Overweight
-
Wells Fargo Starts Pharmasset (VRUS) at Outperform; Could Represent the Future Backbone of HCV Therapy
-
UPDATE - UBS Initiates Coverage on Pharmasset (VRUS) with a Buy; Going NUCLEAR
-
UBS Starts Pharmasset (VRUS) at Buy, $160 Price Target
-
Canaccord Genuity Assumes Coverage on Pharmasset (VRUS) at Buy; Blockbuster Potential of HCV Therapeutic Franchise
-
Brean Murray Carret & Co. Starts Inhibitex (INHX) at Buy, $6 Price Target
-
Brean Murray Carret & Co. Starts Pharmasset (VRUS) at Buy, Price Target Offers 79% Upside
-
William Blair Starts Pharmasset (VRUS) at Outperform
-
Goldman Sachs Starts Pharmasset (VRUS) at Neutral
-
Gleacher & Co Initiates Coverage on Biotechnology/Drug Manufacturers Stocks (IDIX, VRUS, & VRTX)
-
BMO Starts ArQule (ARQL), Pharmasset (VRUS) at Outperform
-
MP Advisors Initiates Coverage on Pharmasset, Inc. (VRUS) with an Outperform
-
JPMorgan Starts Pharmasset (VRUS), InterMune (ITMN) at Overweight
-
Citi Initiates Coverage on Pharmasset (VRUS) with a Buy
-
Bank of America Initiates Coverage on Pharmasset (VRUS) with a Buy.
-
Wedbush Assumes and Initiates Coverage on Several Key Biotech Players in Anti-Viral Space
-
William Blair Initiates Coverage on Pharmasset (VRUS) with an Outperform
-
ThinkPanmure Initiates Coverage on Pharmasset (VRUS) with a Buy
-
Roth Capital Starts Pharmasset (VRUS) at Sell
-
Morgan Stanley Initiates Coverage on Pharmasset (VRUS)
-
Cowen & Co Initiates Coverage on Pharmasset (VRUS) with an Outperform
-
Lazard Starts Pharmasset (VRUS) at Buy
-
Lazard Starts Pharmasset (VRUS) at Buy
-
Pacific Growth Starts Pharmasset (VRUS) at Buy
-
Color on Baird Coverage of Pharmasset (VRUS)
-
Baird Initiates Coverage on Pharmasset (VRUS) with a Neutral
-
Merriman Curhan Initiates Coverage on Pharmasset (VRUS) with a Buy
-
JMP Securities Starts Pharmasset, (VRUS) at Outperform
-
Susquehanna Initiates Coverage on Pharmasset (VRUS) with a Positive
-
UBS Starts Pharmasset (VRUS) with a Buy Rating
-
Stifel Nicolaus Initiates Coverage on Pharmasset (VRUS) with a Buy
-
Banc of America Starts Pharmasset (VRUS) at Buy
Back to VRUS Stock Lookup
